Tumor Biology

, Volume 35, Issue 5, pp 4545–4550 | Cite as

RETRACTED ARTICLE: Lack of association of XRCC1 rs1799782 genetic polymorphism with risk of pancreatic cancer: a meta-analysis

  • Gengsheng He
  • Guodong Chen
  • Wenqi Chen
  • Wei Zhang
  • Jinmin Cao
  • Qifa Ye
Research Article

Abstract

Emerging evidence suggests that genetic polymorphisms in X-ray repair cross-complementation group 1 (XRCC1) gene could be associated with pancreatic cancer risk. However, previous published studies on the association between XRCC1 rs1799782 genetic polymorphism and pancreatic cancer risk reported inconsistent results. For better understanding of the effects of XRCC1 rs1799782 genetic polymorphism on pancreatic cancer risk, we conducted a meta-analysis of previous published studies by calculating the pooled odds ratio (OR) with a 95 % confidence interval (95 % CI). A total of five eligible studies with 1,144 pancreatic cancer cases and 2,925 controls were eventually enrolled. Overall, we found that the XRCC1 rs1799782 genetic polymorphism was not associated with pancreatic cancer risk in total population under all genetic models (TT vs. CC: OR = 1.11, 95 % CI 0.76–1.63, P = 0.583; CT vs. CC: OR = 1.39, 95 % CI 0.92–2.10, P = 0.118; TT/CT vs. CC: OR = 1.39, 95 % CI 0.92–2.10, P = 0.121; TT vs. CT/CC: OR = 1.07, 95 % CI 0.73–1.55, P = 0.743; T vs. C: OR = 1.31, 95 % CI 0.93–1.86, P = 0.125). In the subgroup analysis based on ethnicity, there was no statistically significant association between XRCC1 rs1799782 genetic polymorphism and pancreatic cancer risk in Asians/Caucasians under all genetic models (all P values > 0.05). No publication bias was detected in this study. Our meta-analysis suggests that the XRCC1 rs1799782 genetic polymorphism is not significantly associated with pancreatic cancer risk. Considering the limited sample size and ethnicity enrolled in this meta-analysis, further larger scaled studies are needed to provide a more precise estimation on the association.

Keywords

Pancreatic cancer XRCC1 gene rs1799782 Genetic polymorphism Meta-analysis 

Notes

Acknowledgments

This work was supported by Science and Technology Plan Projects of Hunan Province (2012FJ3105).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer. 2011;117:744–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Nakao M, Hosono S, Ito H, Watanabe M, Mizuno N, Sato S, et al. Selected polymorphisms of base excision repair genes and pancreatic cancer risk in Japanese. J Epidemiol. 2012;22:477–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Yan Y, Chen X, Li T, Li M, Liang H. Association of OGG1 Ser326Cys polymorphism and pancreatic cancer susceptibility: evidence from a meta-analysis. Tumour Biol. 2013. doi: 10.1007/s13277-013-1317-7.
  5. 5.
    Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet. 2003;4:237–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, et al. Molecular and genetic bases of pancreatic cancer. Curr Drug Targets. 2012;13:731–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006;24:1720–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.CrossRefPubMedGoogle Scholar
  9. 9.
    Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007;120:1993–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Luo J, Iwasaki M, Inoue M, Sasazuki S, Otani T, Ye W, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan—the JPHC study. Cancer Causes Control. 2007;18:603–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res. 2002;62:4630–6.PubMedGoogle Scholar
  12. 12.
    Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer. 2007;120:1748–54.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, de Andrade M, Boardman LA, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 2008;68:4928–35.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shen WD, Chen HL, Liu PF. XRCC1 polymorphisms and pancreatic cancer: a meta-analysis. Chin J Cancer Res. 2011;23:165–70.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jiang H, Wu D, Ma D, Lin G, Liang J, Jin J. Association between X-ray repair cross-complementation group 1 rs25487 polymorphism and pancreatic cancer risk. Tumour Biol. 2013;34:3417–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL, et al. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev. 2006;30:284–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang L, Lin DX, Lu XH, Miao XP, Li H. Polymorphisms of the DNA repair genes XRCC1 and XPC: relationship to pancreatic cancer risk. Wei Sheng Yan Jiu. 2006;35:534–6.PubMedGoogle Scholar
  18. 18.
    Yan D, Wang XY, Li HJ, Xu XJ, Zhu GB, He TY. Relationship between single nucleotide polymorphisms and its haplotype of X-ray repair cross complementing group 1 and susceptibility of pancreatic carcinoma. Zhonghua Zhong Liu Za Zhi. 2013;35:472–7.PubMedGoogle Scholar
  19. 19.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMedGoogle Scholar
  21. 21.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.CrossRefPubMedGoogle Scholar
  23. 23.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  25. 25.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Gengsheng He
    • 1
    • 2
  • Guodong Chen
    • 2
  • Wenqi Chen
    • 3
  • Wei Zhang
    • 2
  • Jinmin Cao
    • 2
  • Qifa Ye
    • 1
  1. 1.Center of Transplant Surgery, The Third Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Department of General Surgery, The First Affiliated HospitalUniversity of South ChinaHengyangChina
  3. 3.Department of Oncology, The First Affiliated HospitalUniversity of South ChinaHengyangChina

Personalised recommendations